Vilanterol

Generic Name: Vilanterol

Brand Names: Anoro, Anoro Ellipta, Breo Ellipta, Trelegy Ellipta

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₃₃Cl_₂NO_₅

CAS Number: 503068-34-6

Unique Ingredient Identifier: 028LZY775B

Background: Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug administration). Vilanterol was designe...

Indication: Vilanterol is approved for use in several combination products such as with fluticasone furoate under the tradename Breo Ellipta, in combination with umeclidinium bromide as Anoro Ellipta, and in combination with both fluticasone furoate and umeclidinium under the tradename Trelegy Ellipta.
...

Associated Conditions: Asthma, Chronic Obstructive Pulmonary Disease (COPD)

Associated Therapies: -

Clinical Trials

A Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder With Usual Inhaled Corticosteroids (ICS)/Long Acting Beta Agonists (LABA) in Persistent Asthma

Phase 3

Completed

Conditions: Asthma

Interventions: Drug: Fluticasone Furoate
Drug: Fluticasone propionate
Drug: Vilanterol
Drug: Salmeterol
Drug: Budesonide
Drug: Formoterol Fumarate

First Posted Date: 2015-05-18

Last Posted Date: 2019-01-14

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 423

Registration Number: NCT02446418

Locations: 🇩🇪
GSK Investigational Site, Magdeburg, Germany

Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Phase 3

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Vilanterol
Drug: Fluticasone Furoate/Vilanterol

First Posted Date: 2014-04-07

Last Posted Date: 2018-01-24

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1621

Registration Number: NCT02105974

Locations: 🇺🇦
GSK Investigational Site, Vinnytsia, Ukraine

Study Evaluating the Effect of Fluticasone Furoate/ Vilanterol (FF/VI) Inhalation Powder Compared With Vilanterol (VI) Inhalation Powder on Bone Mineral Density (BMD) in Subjects With Chronic Obstructive Pulmonary Disease (COPD).

Phase 4

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Vilanterol
Drug: Fluticasone Furoate/Vilanterol

First Posted Date: 2013-10-08

Last Posted Date: 2019-04-10

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 283

Registration Number: NCT01957150

Locations: 🇪🇸
GSK Investigational Site, Salamanca, Spain

RELOVAIR® Lung Deflation Study

Phase 3

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Fluticasone Furoate
Drug: Vilanterol

First Posted Date: 2012-09-25

Last Posted Date: 2016-10-27

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 45

Registration Number: NCT01691885

Locations: 🇬🇧
GSK Investigational Site, London, United Kingdom

Dose-ranging Study of Vilanterol (VI) Inhalation Powder in Children

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: Fluticasone propionate 100mcg
Drug: Vilanterol
Drug: Placebo

First Posted Date: 2012-04-10

Last Posted Date: 2017-01-09

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 463

Registration Number: NCT01573767

Locations: 🇺🇦
GSK Investigational Site, Zaporizhia, Ukraine

A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD

Phase 3

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Fluticasone Furoate/Vilanterol
Drug: Vilanterol
Drug: Placebo

First Posted Date: 2011-04-18

Last Posted Date: 2017-11-08

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 446

Registration Number: NCT01336608

Locations: 🇹🇭
GSK Investigational Site, Nan, Thailand

Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease

Phase 3

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: fluticasone furoate
Drug: fluticasone furoate/vilanterol
Drug: vilanterol
Other: Placebo

First Posted Date: 2011-03-14

Last Posted Date: 2018-08-06

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 16568

Registration Number: NCT01313676

Locations: 🇻🇳
GSK Investigational Site, Hue, Vietnam

Study B2C112060: A Study of the Efficacy and Safety of Vilanterol Inhalation Powder in Adults and Adolescents With Persistent Asthma

Phase 3

Completed

Conditions: Asthma

Interventions: Drug: Salmeterol Inhalation Powder
Drug: Vilanterol
Drug: Placebo Inhalation Powder Diskus
Drug: Placebo Inhalation Powder NDPI

First Posted Date: 2010-08-13

Last Posted Date: 2017-11-08

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 348

Registration Number: NCT01181895

Locations: 🇺🇦
GSK Investigational Site, Yalta, Ukraine

Comparing Two Respiratory Drugs in Combination and Separately From a Novel Inhaler Device in Healthy Japanese Subjects

Phase 1

Completed

Conditions: Asthma

Interventions: Drug: Fluticasone foroate/ vilanterol
Drug: Placebo
Drug: Fluticasone foroate
Drug: Vilanterol

First Posted Date: 2008-02-28

Last Posted Date: 2017-08-21

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 16

Registration Number: NCT00625196

Locations: 🇦🇺
GSK Investigational Site, Randwick, New South Wales, Australia

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy